Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Abstract Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including the most detailed analysis of BAP1 alterations to date. We identified histology-independent molecular prognostic subsets, and defined a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity. We also report strong expression of the immune-checkpoint gene VISTA in epithelioid MPM, strikingly higher than in other solid cancers, with implications for the immune response to MPM and for its immunotherapy. Our findings highlight new avenues for further investigation of MPM biology and novel therapeutic options. Significance: Through a comprehensive integrated genomic study of 74 MPMs, we provide a deeper understanding of histology-independent determinants of aggressive behavior, define a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity, and discovered strong expression of the immune-checkpoint gene VISTA in epithelioid MPM. See related commentary by Aggarwal and Albelda, p. 1508. This article is highlighted in the In This Issue feature, p. 1494
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a study that explored 74 mesothelioma tumors using a genomic analysis identified TGF-β1 mRNA expression as being correlated with the worst patient prognoses [40].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053
Self-citationThe Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443 · cited 1×
“Since MPM with evidence of GNH have typically undergone a genome-doubling event, we were able to assess the timing of this relative to point mutations (30,31).”
BackgroundSelf-citationSomatic mutation in cancer and normal cells
Martincorena, I., & Campbell, P. J. (2015) · Science · doi:10.1126/science.aab4082 · Cited by 1,396 · cited 1×
“This places MPM at the low end of somatic mutation burden among cancers (8).”
BackgroundSelf-citationShen, R., & Seshan, V. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw520 · Cited by 1,258
Self-citationBroz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Clock-like mutational processes in human somatic cells
Alexandrov, L. B., Jones, P. H., Wedge, D. C., Sale, J. E., Campbell, P. J., Nik-Zainal, S., & Stratton, M. R. (2015) · Nature Genetics · doi:10.1038/ng.3441 · Cited by 1,058
Self-citationBueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Self-citationShen, R., Olshen, A. B., & Ladanyi, M. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp543 · Cited by 849 · cited 1×
“To find out whether multi-platform molecular profiling might provide additional resolution to define prognostic subsets of MPM, we performed integrative clustering across multiple assay platforms using two algorithms: iCluster (32) and PARADIGM (33).”
MethodSelf-citationVaske, C. J., Benz, S. C., Sanborn, J. Z., Earl, D., Szeto, C., Zhu, J., Haussler, D., & Stuart, J. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq182 · Cited by 786
Self-citation
Cited by
Items 301–400 of 675
Minchom, A. R., Yuan, W., Crespo, M., Gürel, B., Figueiredo, I., Wotherspoon, A. C., Miranda, S., Riisnaes, R., Ferreira, A., Bertan, C. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000713 · Cited by 11
SPaRTAN, a computational framework for linking cell-surface receptors to transcriptional regulators
Ma, X., Somasundaram, A., Qi, Z., Hartman, D. J., Singh, H., & Osmanbeyoglu, H. U. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab745 · Cited by 11
Self-citationSato, T., Nakanishi, H., Akao, K., Okuda, M., Mukai, S., Kiyono, T., & Sekido, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02248-5 · Cited by 11
Self-citationMöhrmann, L., Werner, M., Oleś, M., Knol, L., Arnold, J. S., Mundt, T., Paramasivam, N., Richter, D., Fröhlich, M., Hutter, B., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104532 · Cited by 10
Affatato, R., Mendogni, P., GOBBO, A. D., Ferrero, S., Ricci, F., Broggini, M., & Rosso, L. (2020) · Cancers · doi:10.3390/cancers12123846 · Cited by 10
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Nash, A., & Creaney, J. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01479-1 · Cited by 10
Self-citationGugnoni, M., Lorenzini, E., Torricelli, F., Donati, B., Manicardi, V., Vitale, E., Muccioli, S., Piana, S., Lococo, F., Zamponi, R., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216950 · Cited by 10
Unleashing precision: A review of targeted approaches in pleural mesothelioma
Occhipinti, M. A., Brambilla, M., Liello, R. D., Ambrosini, P., Lobianco, L., Leporati, R., Salvarezza, M., Vitiello, F., Marchesi, S., Manglaviti, S., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104481 · Cited by 10
Blum, Y., Jaurand, M., de Reyniès, A., & Jean, D. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1610322 · Cited by 10
Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
Anobile, D. P., Bironzo, P., Picca, F., Lingua, M. F., Morena, D., Righi, L., Napoli, F., Papotti, M. G., Pittaro, A., Nicolantonio, F. D., et al. (2021) · Cancers · doi:10.3390/cancers13102332 · Cited by 10
Oxytocin receptor is a promising therapeutic target of malignant mesothelioma
Kodama, Y., Tanaka, I., Sato, T., Hori, K., Gen, S., Morise, M., Matsubara, D., Sato, M., Sekido, Y., & Hashimoto, N. (2021) · Cancer Science · doi:10.1111/cas.15025 · Cited by 10
Self-citationMalignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!
Cordier, F., der Meulen, J. V., Roy, N. V., Wilde, J. D., van Dijck, H., Vanhoenacker, F. M. H. M., Lambrechts, M., Noyez, V. J., de Vijver, K. K. V., Ferdinande, L., et al. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153772 · Cited by 10
Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma
Lapidot, M., Saladi, S. V., Salgia, R., & Sattler, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.806570 · Cited by 10
Sculco, M., Vecchia, M. L., Aspesi, A., Clavenna, M. G., Salvo, M., Borgonovi, G., Pittaro, A., Witel, G., Napoli, F., Listì, A., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12071710 · Cited by 10
Paternot, S., Raspé, E., Meiller, C., Tarabichi, M., Assié, J., Libert, F., Remmelink, M., Bisteau, X., Pauwels, P., Blum, Y., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13351 · Cited by 10
Self-citationOncological Frontiers in the Treatment of Malignant Pleural Mesothelioma
Vita, E., Stefani, A., Salvatore, M. D., Chiappetta, M., Lococo, F., Margaritora, S., Tortora, G., & Bria, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112290 · Cited by 10
Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma
Brossel, H., Fontaine, A., Hoyos, C., Jamakhani, M., Willems, M., Hamaïdia, M., & Willems, L. (2021) · Cancers · doi:10.3390/cancers13133211 · Cited by 10
Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition
Cantini, L., Laniado, I., Murthy, V., Sterman, D. H., & Aerts, J. G. J. V. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.016 · Cited by 10
Ceresoli, G. L., & Gianoncelli, L. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01320-w · Cited by 9
De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma
Xu, D., Gao, Y., Liu, S., Yin, S., Hu, T., Deng, H., Zhang, T., Hegedűs, B., Marti, T. M., Dorn, P., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00278-4 · Cited by 9
Steinberg, T., Dieterle, M. P., Ramminger, I., Klein, C., Brossette, J., Husari, A., & Tomakidi, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612677 · Cited by 9
Individualized Cell-Free DNA Monitoring With Chromosomal Junctions for Mesothelioma
Parikh, K., Harris, F. R., Karagouga, G., Schrandt, A., Mandrekar, J. N., Johnson, S. H., McCune, A., Sadeghian, D., Roy, D., Polonis, K., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100692 · Cited by 9
Contemporary management of mesothelioma
Neilly, M. D. J., Pearson, J., Thu, A. W., MacRae, C., & Blyth, K. G. (2024) · Breathe · doi:10.1183/20734735.0175-2023 · Cited by 9
Expanded detection and impact of BAP1 alterations in cancer
Sturgill, I. R., Raab, J. R., & Hoadley, K. A. (2024) · NAR Cancer · doi:10.1093/narcan/zcae045 · Cited by 9
Self-citationCorrelation of Histologic Features with Gene Alterations in Pleural Mesothelioma
Fanaroff, R. E., Yang, S., Tan, K. S., Adusumilli, P. S., Bodd, F. M., Bowman, A. S., Chang, J. C., Offin, M. D., Reiner, A., Rekhtman, N., et al. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100706 · Cited by 9
Self-citationLai, J., Yang, H., & Xu, T. (2021) · BMC Cancer · doi:10.1186/s12885-021-08548-3 · Cited by 9
Immune checkpoint inhibitor therapy for malignant pleural mesothelioma
Nowak, A. K., Chin, W. L., Keam, S., & Cook, A. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.11.006 · Cited by 9
Brandi, G., Straíf, K., Mandrioli, D., Curti, S., Mattioli, S., & Tavolari, S. (2022) · Annals of Global Health · doi:10.5334/aogh.3660 · Cited by 9
Hariharan, A., Qi, W., Rehrauer, H., Wu, L., Ronner, M., Wipplinger, M., Kresoja‐Rakic, J., Sun, S., Oton, L., Sculco, M., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13322 · Cited by 9
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma
Sun, S., Qi, W., Rehrauer, H., Ronner, M., Hariharan, A., Wipplinger, M., Meiller, C., Stahel, R. A., Früh, M., Cerciello, F., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100430 · Cited by 9
Desai, A. P., Kosari, F., Disselhorst, M., Yin, J., Agahi, A., Peikert, T., Udell, J. B. M., Johnson, S. H., Smadbeck, J. B., Murphy, S. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006035 · Cited by 9
Genetic Pathways in Peritoneal Mesothelioma Tumorigenesis
Panagopoulos, I., Andersen, K., Brunetti, M., Gorunova, L., Davidson, B., Lund‐Iversen, M., Micci, F., & Heim, S. (2023) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20388 · Cited by 9
Fennell, D. A. (2019) · Nature · doi:10.1038/d41586-019-02218-y · Cited by 9
Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma
Lee, H., Hamaji, M., Palivela, N., Jang, H.-J., Splawn, T. G., Ramos, D., Lee, A. K., Raghuram, A. C., Ramineni, M., Amos, C. I., et al. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.10.031 · Cited by 9
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology
Chen, H., Tjota, M. Y., Gao, G., Mitchell, O. D., Kindler, H. L., Segal, J. P., Husain, A. N., Mueller, J. S., & Schulte, J. J. (2023) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqad041 · Cited by 9
Self-citationAsbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma
Farahmand, P., Gyurászová, K., Rooney, C., Iraolagoitia, X. L. R., Jayasekera, G., Hedley, A., Johnson, E. R., Chernova, T. A., Malviya, G., HALL, H. G., et al. (2023) · Frontiers in Toxicology · doi:10.3389/ftox.2023.1200650 · Cited by 9
Precision Therapy for Mesothelioma: Feasibility and New Opportunities
Dulloo, S., Bzura, A., & Fennell, D. A. (2021) · Cancers · doi:10.3390/cancers13102347 · Cited by 9
Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?
Carbone, M., Yang, H., & Gaudino, G. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.006 · Cited by 9
Shah, R., Buchmeier, E. L., Kopp, H., Christoph, D. C., Griesinger, F., Reck, M., Hoffknecht, P., Kuon, J., Frost, N., Grohé, C., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108702 · Cited by 8
Ferguson, K., Neilson, M., Mercer, R., King, J., Marshall, K. A., Welch, H. G., Tsim, S., Maskell, N. A., Rahman, N. M., Evison, M., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-067780 · Cited by 8
Yang, S., Jayakumaran, G., Benhamida, J. K., Febres‐Aldana, C. A., Fanaroff, R. E., Chang, J. C., Gedvilaite, E., Villafania, L. B., Sauter, J. L., Offin, M. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0085 · Cited by 8
Self-citationImmunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
Chiec, L. S., & Bruno, D. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910861 · Cited by 8
Vandenhoeck, J., Ibrahim, J., Meulenaere, N. D., Peeters, D. J. E., Raskin, J., Hendriks, J. M. H., Schil, P. E. V., van Meerbeeck, J. P., Camp, G. V., & de Beeck, K. O. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01790-z · Cited by 8
Busacca, S., Zhang, Q., Sharkey, A. J., Dawson, A. G., Moore, D. A., Waller, D. A., Nakas, A., Jones, C., Cain, K., Luo, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-86834-7 · Cited by 8
Self-citationVISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?
Albertsmeier, M., Altendorf-Hofmann, A., Lindner, L. H., Issels, R. D., Kampmann, E., Dürr, H. R., Angele, M. K., Klauschen, F., Werner, J., Jungbluth, A. A., et al. (2022) · Cancers · doi:10.3390/cancers14041006 · Cited by 8
Self-citationAcosta, A. M., Al‐Obaidy, K. I., Sholl, L. M., Ulbright, T. M., & Idrees, M. T. (2022) · Histopathology · doi:10.1111/his.14661 · Cited by 8
KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player
Trassl, L., & Stathopoulos, G. T. (2022) · Cancers · doi:10.3390/cancers14174303 · Cited by 8
Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
Khatib, M. O. A., Pinton, G., Moro, L., & Porta, C. (2023) · Cancers · doi:10.3390/cancers15051537 · Cited by 8
Endo, I., Amatya, V. J., Kushitani, K., Nakagiri, T., Aoe, K., & Takeshima, Y. (2023) · Anticancer Research · doi:10.21873/anticanres.16740 · Cited by 8
SETDB1: Progress and prospects in cancer treatment potential and inhibitor research
Ma, T., Xu, F., Hou, Y., Shu, Y., Zhao, Z., Zhang, Y., Bai, L., Lu, F., & Zhong, L. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107219 · Cited by 8
Mesothelioma Driver Genes, Ferroptosis, and Therapy
Felley‐Bosco, E., & Gray, S. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01318 · Cited by 8
Importance of Cullin4 Ubiquitin Ligase in Malignant Pleural Mesothelioma
Meerang, M., Kreienbühl, J., Orlowski, V., Müller, S. L. C., Kirschner, M. B., & Opitz, I. (2020) · Cancers · doi:10.3390/cancers12113460 · Cited by 8
Pan-cancer investigation of CENPK gene: clinical significance and oncogenic immunology.
Zeng, H., Shen, Y., Hirachan, S., Bhandari, A., & Zhang, X. (2021) · PubMed Central · Cited by 8
Chernova, T. A., Grosso, S., Sun, X. M., Rubio, A., Cabeza, J. Z., Craxton, A., Self, E. L., Nakas, A., Cain, K., MacFarlane, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012469 · Cited by 8
Parisi, A., Rossi, F., Filippis, C. D., Paoloni, F., Felicetti, C., Mammarella, A., Pecci, F., Lupi, A., & Berardi, R. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s272563 · Cited by 8
Rashid, R., Copelli, S., Silverstein, J. C., & Becich, M. J. (2023) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocad132 · Cited by 8
Self-citationHand2 delineates mesothelium progenitors and is reactivated in mesotheliomaPreprint
Prummel, K. D., Crowell, H. L., Nieuwenhuize, S., Brombacher, E. C., Daetwyler, S., Soneson, C., Kresoja‐Rakic, J., Ronner, M., Kocere, A., Ernst, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.11.355693 · Cited by 8
Wirawan, A. (2020) · Institutional Repositories DataBase (IRDB) · Cited by 8
DGAT: a dual-graph attention network for inferring spatial protein landscapes from transcriptomics
Wang, H., Cody, B., Saavedra, M., Faccioli, L. A. P., Florentino, R. M., Soto-Gutierrez, A., & Osmanbeyoglu, H. U. (2026) · Nature Communications · doi:10.1038/s41467-026-73114-z · Cited by 7
Self-citationAlnassar, N., Derry, J. M. J., Banna, G. L., & Górecki, D. C. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-28 · Cited by 7
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights
Kindler, H. L., Dagogo‐Jack, I., de Perrot, M. E., Drazer, M. W., Ismaila, N., & Hassan, R. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00035 · Cited by 7
Self-citationHart, S. A., Alcala, N., Feder, A. F., & Harris, K. (2026) · Communications Biology · doi:10.1038/s42003-026-09652-5 · Cited by 7
Current status and progress in immunotherapy for malignant pleural mesothelioma
Sun, B., Dong, Y., Xu, J., & Wang, Z. (2022) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.18 · Cited by 7
Self-citationSun, R., Tanino, R., Tong, X., Haque, E. F., Amano, Y., Isobe, T., & Tsubata, Y. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-765 · Cited by 7
Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Doe-Tetteh, S. A., Camp, S. Y., Reales, D. N., Crowdis, J. P., Noronha, A. M., Wolff, B., Alano, T., Galle, J., Selçuklu, S. D., Viale, A. J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3247 · Cited by 7
Self-citationSETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53
Xu, M., Tu, Y., Bi, W., Lundberg, M. Z., Klooster, I., Fletcher, J. A., & Ou, W. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02330-x · Cited by 7
Self-citationAssié, J., & Jean, D. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2277224 · Cited by 7
Targeted Approaches to Treatment of Pleural Mesothelioma: A Review
Dagogo‐Jack, I. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00344 · Cited by 7
Malignant Mesothelioma: Mechanism of Carcinogenesis
Kane, A. B., Jean, D., Knuutila, S., & Jaurand, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-30766-0_19 · Cited by 7
Foote, M. B., Shia, J., Zauderer, M. G., Nash, G. M., & Cercek, A. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000399 · Cited by 7
Self-citationAdvances in drug treatments for mesothelioma
Zucali, P. A., Vincenzo, F. D., Perrino, M., Digiacomo, N., Cordua, N., D’Antonio, F., Borea, F., Fazio, R., Pirozzi, A., & Santoro, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2072211 · Cited by 7
Sato, T., Akao, K., Sato, A., Tsujimura, T., Mukai, S., & Sekido, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6056 · Cited by 7
Self-citationFennell, D. A., Griffiths, D., Eminton, Z. B., Morgan-Fox, A., Hill, K., Ewings, S. M., Stuart, C. M., Johnson, L., Mallard, K., Nye, M., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-073120 · Cited by 7
[Advances in Targeted Therapy for Malignant Pleural Mesothelioma].
Fu, F., Zhang, Y., & Shen, H. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.102.18 · Cited by 6
Inflammatory rhabdomyoblastic tumor: A review and update
Folpe, A. L. (2025) · Seminars in Diagnostic Pathology · doi:10.1016/j.semdp.2025.150917 · Cited by 6
BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities
van Genugten, J. H. L. T., Fennell, D. A., & Baas, P. (2026) · Oncogene · doi:10.1038/s41388-025-03672-x · Cited by 6
Torricelli, F., Lococo, F., Stefano, T. S. D., Lorenzini, E., Piana, S., Valli, R., Rena, O., Veronesi, G., Billè, A., & Ciarrocchi, A. (2020) · Cancers · doi:10.3390/cancers12092454 · Cited by 6
KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM)
Lorenzini, E., Torricelli, F., Zamponi, R., Donati, B., Manicardi, V., Sauta, E., do Valle, Í. F., Reggiani, F., Gugnoni, M., Manzotti, G., et al. (2022) · NAR Cancer · doi:10.1093/narcan/zcac024 · Cited by 6
Jama, M., Zhang, M., Poile, C., Nakas, A., Sharkey, A. J., Działo, J., Dawson, A. G., Kutywayo, K. H., Fennell, D. A., & Hollox, E. J. (2023) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23189 · Cited by 6
Haripriya, E., Hemalatha, K., Matada, G. S. P., Pal, R., Das, P. K., Sk, M. D. A., Mounika, S., Viji, M. P., Aayishamma, I., & Jayashree, K. R. (2024) · Molecular Diversity · doi:10.1007/s11030-024-11009-1 · Cited by 6
The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes
Torricelli, F., Spada, F., Bishop, C., Todd, K., Nonaka, D., Petrov, N., Barberio, M. T., Ramsay, A. G., Ellis, R., Ciarrocchi, A., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06193-z · Cited by 6
Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma
Sofianidi, A. A., Syrigos, N. K., Blyth, K. G., Charpidou, A. G., & Vathiotis, I. A. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.04.008 · Cited by 6
Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival
Zhang, L., & Huang, M. (2025) · MedComm · doi:10.1002/mco2.70327 · Cited by 6
Xu, H., Shen, K., Jiang, B., Xu, Q., Li, B., Ke, Z., Cheng, Q., Zhu, S., Wang, D., Song, Y., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06818-3 · Cited by 6
Louw, A., Lee, G., Acott, N., Creaney, J., Vliet, C. V., & Chai, S. M. (2021) · Cytopathology · doi:10.1111/cyt.13015 · Cited by 6
Self-citationJohnson, B., Takahashi, K., & Cheng, Y. Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.748444 · Cited by 6
Santoni‐Rugiu, E., Lü, M. J. S., Jakobsen, J. N., Melchior, L. C., Ravn, J. B., & Sørensen, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312868 · Cited by 6
Martens, M., Kreidl, F., Ehrhart, F., Jean, D., Mei, M., Mortensen, H. M., Nash, A., Nymark, P. E. H., Evelo, C. T., & Cerciello, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.849640 · Cited by 6
Stern, E., Caruso, S., Meiller, C., Mishalian, I., Hirsch, T. Z., Bayard, Q., Tadmor, C. T., Wald, H., Jean, D., & Wald, O. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026185 · Cited by 6
An update in malignant peritoneal mesothelioma diagnosis and treatment—a narrative review
Newland, J. J., Molin, M. D., & Terhune, J. H. (2023) · AME Surgical Journal · doi:10.21037/asj-22-37 · Cited by 6
The therapeutic implications of the genomic analysis of malignant pleural mesothelioma
Zauderer, M. G. (2021) · Nature Communications · doi:10.1038/s41467-021-22142-y · Cited by 6
Self-citationNguyen, T. T., Lee, H., Burt, B. M., Amos, C. I., & Cheng, C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01950-z · Cited by 6
Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma
Fan, X., McLaughlin, C., Robinson, C., Ravasini, J., Schelch, K., Johnson, T. G., van Zandwijk, N., Reid, G., & George, A. M. (2019) · FASEB BioAdvances · doi:10.1096/fba.2019-00040 · Cited by 6
Self-citationMicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma
Kim, K., Ko, Y., Oh, H., Ha, M., Kang, J., Kwon, E. J., Kang, J. W., Kim, Y., Heo, H. J., Kim, J., et al. (2020) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2020.1734891 · Cited by 6
Self-citationNivolumab activity in advanced refractory malignant peritoneal mesothelioma
Becker, O., Beaulaton, C., Masliah‐Planchon, J., Servois, V., & Watson, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.024 · Cited by 6
Behrouzfar, K., Burton, K., Mutsaers, S. E., Morahan, G., Lake, R., & Fisher, S. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679609 · Cited by 6
Abukar, A., Wipplinger, M., Hariharan, A., Sun, S., Ronner, M., Sculco, M., Okonska, A., Kresoja‐Rakic, J., Rehrauer, H., Qi, W., et al. (2021) · Cells · doi:10.3390/cells10123543 · Cited by 6
Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions
Felley‐Bosco, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113560 · Cited by 6
Malignant Pleural Mesothelioma
Carbone, M., Gomez, D. R., Tsao, A. S., Yang, H., & Pass, H. I. (2023) · Wiley eBooks · doi:10.1002/9781119000822.hfcm086.pub2 · Cited by 6
Self-citationComputational prediction of therapeutic response and cancer outcomesPreprint
Griffiths, M., Kubeyev, A., Laurie, J., Giorni, A., da Silva, L. A. Z., Sivasubramaniam, P., Foster, M. T., Biankin, A. V., & Asghar, U. S. (2024) · medRxiv · doi:10.1101/2024.01.17.24301444 · Cited by 6
Metadata
- Authors
- Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., Bowlby, R., Kanchi, R., Osmanbeyoglu, H. U., Sekido, Y., Takeshita, J., Newton, Y., Graim, K., Gupta, M., Gay, C. M., Diao, L., Gibbs, D. L., Thorsson, V., Iype, L., Kantheti, H., Severson, D. T., Ravegnini, G., Desmeules, P., Jungbluth, A. A., Travis, W. D., Dacic, S., Chirieac, L. R., Galateau-Sallé, F., Fujimoto, J., Husain, A. N., Silveira, H. C., Rusch, V. W., Rintoul, R. C., Pass, H., Kindler, H., Zauderer, M. G., Kwiatkowski, D. J., Bueno, R., Tsao, A. S., Creaney, J., Lichtenberg, T., Leraas, K., Bowen, J., TCGA Research Network, Felau, I., Zenklusen, J. C., Akbani, R., Cherniack, A. D., Byers, L. A., Noble, M. S., Fletcher, J. A., Robertson, A. G., Shen, R., Aburatani, H., Robinson, B. W., Campbell, P., Ladanyi, M., Aburatani, H., Akbani, R., Ally, A., Anur, P., Armenia, J., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., Becich, M., Behrens, C., Beroukhim, R., Bielski, C., Bodenheimer, T., Bootwalla, M. S., Bowen, J., Bowlby, R., Brooks, D., Bueno, R., Byers, L. A., Cárcano, F. M., Carlsen, R., Carvalho, A. L., Cherniack, A. D., Cheung, D., Chirieac, L., Cho, J., Chuah, E., Chudamani, S., Cibulskis, C., Cope, L., Crain, D., Creaney, J., Curley, E., Dacic, S., Danilova, L., Rienzo, A. D., DeFreitas, T., Demchok, J. A., Dhalla, N., Dhir, R., Diao, L., Drill, E., Felau, I., Feldman, M., Ferguson, M. L., Fletcher, J. A., Fujimoto, J., Fujimoto, J., Fukuda, S., Gabriel, S. B., Sallé, F. G., Gao, J., Gardner, J., Gastier-Foster, J. M., Gay, C. M., Gehlenborg, N., Gerken, M., Getz, G., Gibb, E. A., Gibbs, D. L., Goparaju, C., Graim, K., Gross, B., Guo, G., Gupta, M., Hasegawa, S., Haussler, D., Hayes, D. N., Heiman, D. I., Heins, Z., Hmeljak, J., Hoadley, K. A., Holt, R. A., Hoyle, A. P., Husain, A., Hutter, C. M., Iype, L., Jefferys, S. R., Jones, S. J. M., Jones, C. D., Kanchi, R. S., Kasaian, K., Kim, J., Kindler, H., Kondo, N., Krausz, T., Kundra, R., Kuribayashi, K., Kwiatkowski, D. J., Ladanyi, M., Lai, P. H., Laird, P. W., Lawrence, M. S., Lee, D., Leraas, K. M., Lichtenberg, T. M., Lin, P., Liu, J., Liu, W., Liu, E. M., Lolla, L., Longatto-Filho, A., Lu, Y., Luketich, J., Ma, Y., Maglinte, D. T., Mallory, D., Marra, M. A., Mayo, M., Meier, S., Melamed, J., Meng, S., Meyerson, M., Mieczkowski, P. A., Mills, G. B., Moore, R. A., Moran, C., Morris, S., Mose, L. E., Mungall, A. J., Mungall, K., Nakano, T., Naresh, R., Newton, Y., Noble, M. S., Ochoa, A., Osmanbeyoglu, H., Parker, J. S., Pass, H. I., Paulauskis, J., Pennathur, A., Pennell, N. A., Penny, R., Perou, C. M., Pihl, T., Ramirez, N. C., Rassl, D. M., Ravegnini, G., Reid, G., Reis, R. M., Reynolds, S. M., Rice, D., Richards, W. G., Rintoul, R. C., Roach, J., Robertson, A. G., Rusch, V., Sadeghi, S., Saksena, G., Sanchez-Vega, F., Sander, C., Sato, A., Scapulatempo-Neto, C., Schein, J. E., Schultz, N., Schumacher, S. E., Seiwert, T., Sekido, Y., Severson, D. T., Shelton, C., Shelton, T., Shen, R., Sheridan, R., Shi, Y., Shih, J., Shiraishi, Y., Shmulevich, I., Silveira, H. C. S., Simons, J. V., Sipahimalani, P., Skelly, T., Sofia, H. J., Soloway, M. G., Spellman, P., Stewart, C., Stuart, J., Sun, Q., Takeshita, J., Tam, A., Tan, D., Tarnuzzer, R., Tatsuno, K., Taylor, B. S., Thiessen, N., Thompson, E., Thorsson, V., Travis, W. D., Tsao, A., Tse, K., Tsujimura, T., Valdivieso, F., Van Den Berg, D. J., van Zandwijk, N., Veluvolu, U., Viana, L. S., Voet, D., Wan, Y., Wang, Z., Wang, J., Weaver, J., Weinstein, J. N., Weisenberger, D. J., Wilkerson, M. D., Wise, L., Wistuba, I., Wong, T., Wu, Y., Yamamoto, S., Yang, L., Zauderer, M. G., Zenklusen, J. C., Zhang, J., Zhang, H., Zhang, H., & Zmuda, E.
- Affiliations
- 3Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
- Wellcome Sanger Institute (GB)
- 10Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 11Computational Systems Biology, Memorial Sloan Kettering Cancer Center, New York, New York.
- The University of Texas at Dallas (US)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Memorial Sloan Kettering Cancer Center (US)
- 23Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
- 24MESOPATH. Cancer Center Leon Berard, Lyon, France.
- 26Department of Pathology, University of Chicago, Chicago, Illinois.
- 27Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil.
- 28Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
- 30Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, New York.
- 15Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 35The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
- 36National Cancer Institute, Bethesda, Maryland.
- 18Division of Thoracic Surgery, The Lung Center and International Mesothelioma Program, Brigham and Women's Hospital, Boston, Massachusetts.
- The University of Western Australia (AU)
- ORCID
- Tarpey, Patrick
- Kantheti, Havish
- Desmeules, Patrice
- Jungbluth, Achim A.
- Silveira, Henrique C.
- Tsao, Anne S.
- Robinson, Bruce W.
- Campbell, Peter
- Armenia, Joshua
- Auman, J. Todd
- Baylin, Stephen B.
- Becich, Michael
- Behrens, Carmen
- Beroukhim, Rameen
- Bootwalla, Moiz S.
- Cibulskis, Carrie
- Cope, Leslie
- Rienzo, Assunta De
- Dhir, Rajiv
- Ferguson, Martin L.
- Fukuda, Shiro
- Gabriel, Stacey B.
- Gao, Jianjiong
- Gehlenborg, Nils
- Getz, Gad
- Goparaju, Chandra
- Gross, Benjamin
- Guo, Guangwu
- Hasegawa, Seiki
- Haussler, David
- Hayes, D. Neil
- Heins, Zachary
- Holt, Robert A.
- Hoyle, Alan P.
- Jefferys, Stuart R.
- Jones, Steven J.M.
- Jones, Corbin D.
- Kasaian, Katayoon
- Kim, Jaegil
- Kondo, Nobuyuki
- Kundra, Ritika
- Kuribayashi, Kozo
- Laird, Peter W.
- Lawrence, Michael S.
- Lee, Darlene
- Lin, Pei
- Liu, Jia
- Liu, Wenbin
- Liu, Eric Minwei
- Lu, Yiling
- Luketich, James
- Maglinte, Dennis T.
- Marra, Marco A.
- Mayo, Michael
- Melamed, Jonathan
- Meyerson, Matthew
- Mieczkowski, Piotr A.
- Mills, Gordon B.
- Mungall, Andrew J.
- Nakano, Takashi
- Ochoa, Angelica
- Parker, Joel S.
- Pennathur, Arjun
- Pennell, Nathan A.
- Perou, Charles M.
- Pihl, Todd
- Ramirez, Nilsa C.
- Rassl, Doris M.
- Reid, Glen
- Reis, Rui M.
- Rice, David
- Richards, William G
- Roach, Jeffrey
- Sadeghi, Sara
- Saksena, Gordon
- Sander, Chris
- Sato, Ayuko
- Schultz, Nikolaus
- Schumacher, Steven E.
- Seiwert, Tanguy
- Shi, Yan
- Shiraishi, Yuichi
- Sofia, Heidi J.
- Spellman, Paul
- Sun, Qiang
- Tam, Angela
- Tarnuzzer, Roy
- Tatsuno, Kenji
- Taylor, Barry S
- Tsujimura, Tohru
- Wang, Jing
- Weaver, Joellen
- Weinstein, John N.
- Weisenberger, Daniel J.
- Wilkerson, Matthew D.
- Wistuba, Ignacio
- Wong, Tina
- Wu, Ye
- Yamamoto, Shogo
- Yang, Liming
- Zhang, Jiashan
- Zhang, Hailei
- Zhang, Hongxin
- Zmuda, Erik
- Venue
- Cancer Discovery
- Published
- 2018-12-01
- Volume
- 8
- Issue
- 12
- Pages
- 1548-1565
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6310008
- OpenAlex
- W2897299514
- Cited by
- 618
- References
- 62
- Citations by year
- 2026: 53 · 2025: 62 · 2024: 61 · 2023: 78 · 2022: 96 · 2021: 117 · 2020: 100 · 2019: 45 · 2018: 4
- FWCI
- 50.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Funders
- HHS | National Institutes of Health (NIH) (U54 HG003273, U24 CA143858, U24 CA143866, U24 CA143867, U24 CA143882, U24 CA143883, U24 CA144025, P30 CA016672, P30 CA008748, U54 HG003067, U54 HG003079, U24 CA143799, U24 CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848)
- British Lung Foundation (BLF) (APG11-7)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- malignant pleural mesothelioma, TP53 mutation, loss of heterozygosity, genomic subtypes, VISTA, immune checkpoint, epithelioid mesothelioma, immunotherapy, antitumor immunity
- MeSH terms
- Aged, Female, Humans, Lung Neoplasms, Male, Mesothelioma, Middle Aged, Mutation, Pleural Neoplasms, Prognosis, Histone-Lysine N-Methyltransferase, Protein Methyltransferases, Biomarkers, Tumor, Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.